News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Incyte Corporation Arthritis Drug Shows Promise; Positive Phase 2 Data Triggers $30 Million Milestone from Eli Lilly and Company
May 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Biotechnology firm Incyte Corp said data from a mid-stage trial of its experimental rheumatoid arthritis treatment showed the drug was safe and effective.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Clinical research
Phase II
Eli Lilly and Company
Incyte
MORE ON THIS TOPIC
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
September 3, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Novartis Continues Cutting Spree With 58 Sacked in New Jersey
September 3, 2025
·
195 min read
·
BioSpace Editorial Staff
Cardiovascular disease
Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study
September 3, 2025
·
2 min read
·
Tristan Manalac
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
September 2, 2025
·
2 min read
·
Heather McKenzie
